XJPX4597
Market cap48mUSD
Jan 22, Last price
35.00JPY
1D
0.00%
1Q
-12.50%
IPO
-85.29%
Name
Solasia Pharma KK
Chart & Performance
P/E
—
P/S
12.37
EPS
—
Div Yield, %
—
Shrs. gr., 5y
12.52%
Rev. gr., 5y
14.18%
Revenues
617m
-43.50%
Net income
-1.11b
L-56.36%
CFO
-359m
L-82.69%
Profile
Solasia Pharma K.K. develops and commercializes drugs in the field of oncology in Japan and other Asian countries. The company offers SP-03 (episil oral liquid) for the protection and relief of oral pain associated with oral mucositis/stomatitis caused by chemotherapy and radiotherapy for cancer; and SP-01 (Sancuso), a transdermal delivery system that delivers granisetron, an anti-emetic into the patient's bloodstream for the treatment of chemotherapy induced nausea and vomiting. It is also developing SP-02 (Darinaparsin), a mitochondrial-targeted agent that has completed phase III clinical study to treat various hematologic and solid cancers; and SP-04 a chemotherapy induced peripheral neuropathy which is in pre-clinical stage. In addition, the company is developing SP-05 (Arfolitixorin) that is in phase III clinical study for the enhancement of antitumor efficacy of fluorouracil, including the treatment for pancreatic cancer, breast cancer, stomach cancer, and head and neck cancers. Solasia Pharma K.K. was founded in 2006 and is based in Tokyo, Japan.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 617,000 -43.50% | 1,092,000 95.35% | |||||||
Cost of revenue | 1,756,000 | 3,563,000 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (1,139,000) | (2,471,000) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (22,000) | 56,000 | |||||||
Tax Rate | |||||||||
NOPAT | (1,117,000) | (2,527,000) | |||||||
Net income | (1,112,000) -56.36% | (2,548,000) 2.87% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 318,000 | 2,615,000 | |||||||
BB yield | -4.20% | -35.11% | |||||||
| Debt | |||||||||
Debt current | 33,000 | 37,000 | |||||||
Long-term debt | 87,000 | 37,000 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | 331,000 | 12,000 | |||||||
Net debt | (614,000) | (740,000) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (359,000) | (2,074,000) | |||||||
CAPEX | (403,000) | ||||||||
Cash from investing activities | 2,000 | (418,000) | |||||||
Cash from financing activities | 275,000 | 2,571,000 | |||||||
FCF | (873,000) | (2,732,000) | |||||||
| Balance | |||||||||
Cash | 728,000 | 803,000 | |||||||
Long term investments | 6,000 | 11,000 | |||||||
Excess cash | 703,150 | 759,400 | |||||||
Stockholders' equity | 286,000 | 1,231,000 | |||||||
Invested Capital | 1,660,000 | 1,951,600 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 168,132 | 151,987 | |||||||
Price | 45.00 -8.16% | 49.00 -54.21% | |||||||
Market cap | 7,565,936 1.59% | 7,447,358 -46.52% | |||||||
EV | 6,951,936 | 6,707,358 | |||||||
EBITDA | (639,000) | (1,937,000) | |||||||
EV/EBITDA | |||||||||
Interest | 18,000 | ||||||||
Interest/NOPBT | |||||||||